PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24361227-0	2014	Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.	Paclitaxel	145-155	ribonucleotide reductase catalytic subunit M1	Homo sapiens	46-50	
31068300-0	2019	[Silencing RRM1 gene reverses paclitaxel resistance in human breast cancer cell line MCF- 7/R by inducing cell apoptosis].	Paclitaxel	30-40	ribonucleotide reductase catalytic subunit M1	Homo sapiens	11-15	
31068300-9	2019	Transfection with the specific siRNAs significantly reduced the expression of RRM1 in MCF-7/R cells (P < 0.05), which showed a significantly lower IC50 value of paclitaxel than the cells transfected with the negative control siRNA (P < 0.05).	Paclitaxel	168-178	ribonucleotide reductase catalytic subunit M1	Homo sapiens	78-82	
31068300-10	2019	RRM1 silencing significantly inhibited the proliferation (P < 0.01) and enhanced the apoptosis-inducing effect of paclitaxel in MCF-7/R cells (P < 0.001); RRM1 silencing also resulted in obviously reduced Akt phosphorylation, suppressed Bcl-2 expression and promoted the expression of p53 protein in MCF-7/R cells.	Paclitaxel	121-131	ribonucleotide reductase catalytic subunit M1	Homo sapiens	0-4	
31068300-10	2019	RRM1 silencing significantly inhibited the proliferation (P < 0.01) and enhanced the apoptosis-inducing effect of paclitaxel in MCF-7/R cells (P < 0.001); RRM1 silencing also resulted in obviously reduced Akt phosphorylation, suppressed Bcl-2 expression and promoted the expression of p53 protein in MCF-7/R cells.	Paclitaxel	121-131	ribonucleotide reductase catalytic subunit M1	Homo sapiens	169-173	
31068300-12	2019	CONCLUSIONS: RRM1 gene silencing can reverse paclitaxel resistance in human breast cancer cell line MCF-7/R by promoting cell apoptosis.	Paclitaxel	45-55	ribonucleotide reductase catalytic subunit M1	Homo sapiens	13-17	
19945225-6	2010	RESULTS: Omicronbjective response rate was notably better when paclitaxel was used as every three weeks regimen (7 studies, 1772 patients, fixed effect model pooled RR 1.20 95%CI 1.08-1.32 p<0.001).	Paclitaxel	63-73	ribonucleotide reductase catalytic subunit M1	Homo sapiens	165-169	
34603450-4	2021	The mRNA expression of RRM1, TUBB3, and ERCC1 was detected in the experimental group before chemotherapy, and based on the detected expression, the chemotherapy regimen of cisplatin plus gemcitabine or cisplatin plus paclitaxel was chosen.	Paclitaxel	217-227	ribonucleotide reductase catalytic subunit M1	Homo sapiens	23-27	
34603450-9	2021	In the detected group, the prognosis of patients with low expression of RRM1 was better than that of patients with high expression of RRM1 after paclitaxel treatment (P=0.0039).	Paclitaxel	145-155	ribonucleotide reductase catalytic subunit M1	Homo sapiens	72-76	
34603450-9	2021	In the detected group, the prognosis of patients with low expression of RRM1 was better than that of patients with high expression of RRM1 after paclitaxel treatment (P=0.0039).	Paclitaxel	145-155	ribonucleotide reductase catalytic subunit M1	Homo sapiens	134-138